Label
No interactions expected
Color
Green
Green: Administer standard doses
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine (IM) Metformin | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Digoxin | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Tenofovir disoproxil fumarate | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Raltegravir | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Darunavir/ritonavir | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Acetaminophen | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Omeprazole | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) SOF/VEL | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Famotidine | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) SOF | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Chlorzoxazone | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Sildenafil | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Ethinyl estradiol / Norethindrone acetate | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) DTG | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Atorvastatin | Green: Administer standard doses | Administer standard doses | |||||
| Rilpivirine (IM) Aluminum and magnesium hydroxide antacid | Green: Administer standard doses | Administer standard doses | |||||
| Lenacapavir Pitavastatin 1 | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
Not reported |
2 mg x 1 (with food), administered 3 days after LEN | AUC decreased 4% |
|
| Lenacapavir Voriconazole | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
AUC increased 41%; Cmax increased 9% |
400 mg BID x 2 days then 200 mg BID | Not reported |
|
| Lenacapavir Tenofovir alafenamide | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
Not reported |
25 mg x 1 | TAF AUC increased 32%; Cmax increased 24%. TFV AUC increased 47%; Cmax increased 23% |
|
| Lenacapavir Rosuvastatin | Green: Administer standard doses | Administer standard doses | Potential for increased rosuvastatin adverse effects (e.g. myalgias, increased transaminases) |
Not reported |
5 mg orally x 1 | AUC increased 31%; Cmax increased 57% |
|
| Lenacapavir Pitavastatin | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
Not reported |
2 mg x 1 (with food, simultaneous administration with oral LEN) | AUC increased 11% |
|
| Lenacapavir Famotidine | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
AUC increased 28% |
40 mg daily | Not reported |
|
| Lenacapavir Darunavir/cobicistat | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
AUC increased 94%; Cmax increased 130% |
800/150 mg once daily (in fed state) | Not reported |
|
| Ritonavir Escitalopram 1069 | Green: Administer standard doses | Administer standard doses | No significant change |
20 mg x 1 dose | No significant change |
||
| Ritonavir Cetirizine 1068 | Green: Administer standard doses | Administer standard doses | Not studied |
10 mg daily | Cetirizine AUC increased 42%; half-life: increased 52%; clearance: decreased 29%; Cmax no significant change |
||
| Ritonavir Mefloquine 1067 | Green: Administer standard doses | Administer standard doses | AUC decreased 31%; Cmax increased 36%; Cmin decreased 43% |
250 mg daily x 3 days, then once weekly for 3 weeks | No significant change |
||
| Ritonavir Fluconazole 1066 | Green: Administer standard doses | Administer standard doses | Cmax increased 14.5%; AUC increased 12%; Cmin increased 14% |
400 mg x 1 day, then 200 mg days 2-5 | |||
| Ritonavir RAL 1065 | Green: Administer standard doses | Administer standard doses | 400 mg x 1 | Raltegravir AUC decreased 16%; Cmax decreased 24% |
|||
| Ritonavir TMP/SMX 1064 | Green: Administer standard doses | Administer standard doses | 160 mg / 800 mg x 1 dose | Sulfamethoxazole AUC decreased 20%; trimethoprim AUC increased 20% |
|||
| Ritonavir Posaconazole 1063 | Green: Administer standard doses | Administer standard doses | Potential increased ritonavir effects |
Ritonavir AUC increased 80%; Cmax increased 49% |
400 mg BID | ||
| Ritonavir Fluoxetine 1062 | Green: Administer standard doses | Administer standard doses | Increased ritonavir effects; Potential increased fluoxetine effects |
AUC increased 19%; Cmax no significant change |
30 mg Q12H | ||
| Ritonavir Beclomethasone 1061 | Green: Administer standard doses | Administer standard doses | Not studied |
160 mcg inhaled BID | Beclomethasone-17-monopriopionate AUC increased 108%; Cmax increased 67% |
Use lowest possible dose and titrate to effect |
|
| Ritonavir EFV 1060 | Green: Administer standard doses | Administer standard doses | Possible increased effects of both drugs |
Ritonavir AUC increased 18% |
600 mg daily | Efavirenz AUC increased 21% |
No dose adjustment required for boosting doses of ritonavir |
| Ritonavir Dabigatran 1059 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
Not studied |
Not studied (may increase dabigatran levels) |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|
| Ritonavir Zolpidem 1058 | Green: Administer standard doses | Administer standard doses | Increased zolpidem effects (eg, increased sedation, confusion) |
5 mg x 1 dose | Zolpidem AUC increased 28%; Cmax increased 22% |
Monitor for excess sedation |
|
| Ritonavir Levothyroxine 1057 | Green: Administer standard doses | Administer standard doses | Increased TSH levels (eg, Signs and symptoms of hypothyroidism) |
0.125 mg | Monitor and increase levothyroxine dose as indicated |
||
| Ritonavir Desipramine 1056 | Green: Administer standard doses | Administer standard doses | Increased desipramine effects (eg, dry mouth, dizziness, urinary retention) |
Not studied |
Desipramine clearance: decreased 59% |
Monitor and adjust desipramine as indicated |
|
| Ritonavir Amitriptyline 1055 | Green: Administer standard doses | Administer standard doses | Increased amitriptyline effects (eg, dry mouth, hypotension, confusion) |
Not studied |
Not studied (may increase amitriptyline levels) |
Monitor and adjust amitriptyline as indicated |
|
| Ritonavir Prednisolone 1054 | Green: Administer standard doses | Administer standard doses | Potential increased prednisolone effects (adrenal insufficiency, Cushing's syndrome). |
20 mg x 1 dose | Prednisolone AUC increased 30%; clearance: decreased 23% |
Do not coadminister unless potential benefits of prednisone outweigh the risks of systemic corticosteroid adverse effects. |
|
| Darunavir Z-Pak 918 | Green: Administer standard doses | Administer standard doses | |||||
| Darunavir ETR 917 | Green: Administer standard doses | Administer standard doses | 200 mg twice daily | ||||
| Darunavir SOF/VEL 916 | Green: Administer standard doses | Administer standard doses | Cmax decrease 10%, AUC decrease 8%, Cmin decrease 13%. |
400 / 100 mg | Sofosbuvir Cmax decrease 38%, AUC decrease 28%; Velpatasvir Cmax decrease 24%, AUC decrease 16%. |
||
| Darunavir Omeprazole 915 | Green: Administer standard doses | Administer standard doses | No significant change |
20 mg once daily | Not reported |
||
| Darunavir Ranitidine 914 | Green: Administer standard doses | Administer standard doses | No significant change |
150 mg BID | Not reported |
||
| Darunavir LDV/SOF 913 | Green: Administer standard doses | Administer standard doses | No significant change |
90 / 400 mg once daily | Ledipasvir Cmax increase 45%, AUC increase 39%, Cmin increase 39%; Sofosbuvir Cmax increase 45%, AUC increase 34% |
||
| Darunavir SOF 912 | Green: Administer standard doses | Administer standard doses | No significant change |
400 mg x 1 | Cmax increase 45%, AUC increase 34% |
||
| Darunavir TDF 911 | Green: Administer standard doses | Administer standard doses | Cmax increase 16%, AUC increase 21%, Cmin increase 24% |
300 mg once daily | Cmax increase 24%, AUC increase 22%, Cmin increase 37% |
||
| Darunavir NVP 910 | Green: Administer standard doses | Administer standard doses | Cmax increase 40%, AUC increase 24%, Cmin increase 2% |
200 mg BID | Cmax increase 18%, AUC increase 27%, Cmin increase 47% |
||
| Darunavir EFV 909 | Green: Administer standard doses | Administer standard doses | Cmax decrease 15%, AUC decrease 13%, Cmin decrease 31% |
600 mg once daily | Cmax increase 15%, AUC increase 21%, Cmin increase 17% |
||
| Darunavir ETR 908 | Green: Administer standard doses | Administer standard doses | Not reported |
100 mg BID | Cmax decrease 32%, AUC decrease 37%, Cmin decrease 49% |
||
| Darunavir DTG 907 | Green: Administer standard doses | Administer standard doses | No significant change |
30 mg once daily | Cmax decrease 11%, AUC decrease 22%, Cmin decrease 38% |
||
| Darunavir ATV 906 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg once daily | Cmax decrease 11%, AUC increase 8%, Cmin increase 52% |
||
| Darunavir Pitavastatin 905 | Green: Administer standard doses | Administer standard doses | No significant change |
4 mg once daily | AUC decreased 26% |
||
| Darunavir RPV 904 | Green: Administer standard doses | Administer standard doses | Potential for increased rilpivirine adverse effects |
No significant change |
150 mg once daily | Cmax decrease 21%, AUC increase 130%, Cmin increase 178% |
|
| Darunavir Beclomethasone 903 | Green: Administer standard doses | Administer standard doses | Not reported |
160 mcg inhaled BID | No change in AUC of active metabolite |
Use lowest possible dose and titrate to effect |
|
| Darunavir Daclatasvir 902 | Green: Administer standard doses | Administer standard doses | No significant change |
30 mg once daily | No significant change |
No dose adjustment necessary |
|
| Darunavir Edoxaban 901 | Green: Administer standard doses | Administer standard doses | No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
||||
| Darunavir Dabigatran 900 | Green: Administer standard doses | Administer standard doses | No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
||||
| Atazanavir Acetaminophen 816 | Green: Administer standard doses | Administer standard doses | Atazanavir Cmin increased 26% |
1 gram BID on days 1-20 | |||
| Atazanavir Ketoconazole 815 | Green: Administer standard doses | Administer standard doses | No significant change |
200 mg daily on days 7-13 | Not reported |
||
| Atazanavir Fluconazole 814 | Green: Administer standard doses | Administer standard doses | No significant change |
200 mg daily x 10 days | No significant change |
||
| Atazanavir Atenolol 813 | Green: Administer standard doses | Administer standard doses | Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 26% |
50 mg daily on days 7-11 and 19-23 | Atenolol AUC increased 25%, Cmax increased 34%, Cmin no significant change |
||
| Atazanavir SOF/VEL 812 | Green: Administer standard doses | Administer standard doses | Atazanavir Cmax increased 9%, AUC increased 20%, Cmin increased 39%. |
400 mg / 100 mg | Sofosbuvir AUC increased 22%. Velpatasvir Cmax increased 55%, AUC increased 142%, Cmin increased 301% |
||
| Atazanavir DTG 811 | Green: Administer standard doses | Administer standard doses | Not reported |
30 mg daily | Dolutegravir AUC increased 91%, Cmax increased 50%, Cmin increased 180% |
||
| Atazanavir DTG 810 | Green: Administer standard doses | Administer standard doses | Not reported |
30 mg daily | Dolutegravir AUC increased 62%, Cmax increased 34%, Cmin increased 121% |
||
| Atazanavir Dabigatran 809 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|||
| Atazanavir Dabigatran 808 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|||
| Atazanavir Rosiglitazone 807 | Green: Administer standard doses | Administer standard doses | Potential for increased rosiglitazone adverse effects |
4 mg x 1 | Rosiglitazone AUC increased 35% |
Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir |
|
| Atazanavir Rosiglitazone 806 | Green: Administer standard doses | Administer standard doses | Potential decreased glycemic control |
4 mg x 1 | Rosiglitazone AUC decreased 17% |
Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir |
|
| Atazanavir Posaconazole 805 | Green: Administer standard doses | Administer standard doses | Potential for increased atazanavir adverse effects |
Atazanavir AUC increased 268%, Cmax increased 155% |
400 mg BID | Monitor closely for atazanavir adverse effects during coadministration |
|
| Atazanavir Posaconazole 804 | Green: Administer standard doses | Administer standard doses | Potential for increased atazanavir adverse effects |
Atazanavir AUC increased 146%, Cmax increased 53% |
400 mg BID | Monitor closely for atazanavir adverse effects during coadministration |
|
| Atazanavir LDV/SOF 803 | Green: Administer standard doses | Administer standard doses | Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir. |
Atazanavir AUC increased 27%, Cmin increased 63% |
90 / 400 mg | Ledipasvir AUC(tau) increased 96%, Cmax increased 68%. |
If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen. |
| Atazanavir LDV/SOF 802 | Green: Administer standard doses | Administer standard doses | Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir. |
Atazanavir AUC(tau) increased 43% |
90 / 400 mg | Ledipasvir AUC(tau) increased 134%, Cmax increased 75% |
If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen. |
| Tenofovir disoproxil fumarate Ribavirin 746 | Green: Administer standard doses | Administer standard doses | No significant change |
800 mg x 1 | No significant change |
||
| Tenofovir disoproxil fumarate RIF 745 | Green: Administer standard doses | Administer standard doses | No significant change |
600 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate EFV 744 | Green: Administer standard doses | Administer standard doses | No significant change |
600 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate Daclatasvir 743 | Green: Administer standard doses | Administer standard doses | No significant change |
60 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate DTG 742 | Green: Administer standard doses | Administer standard doses | No significant change |
50 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate Methadone 741 | Green: Administer standard doses | Administer standard doses | Not studied |
40-110 mg once daily (individual patients on stable dose) | No significant change |
||
| Tenofovir disoproxil fumarate ABC 740 | Green: Administer standard doses | Administer standard doses | No significant change |
300 mg x 1 | No significant change |
||
| Tenofovir disoproxil fumarate FTC 739 | Green: Administer standard doses | Administer standard doses | No significant change |
200 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate Buprenorphine / naloxone 738 | Green: Administer standard doses | Administer standard doses | No significant change |
14-16 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate EE/NGM 737 | Green: Administer standard doses | Administer standard doses | No significant change |
1 tab daily | No significant change |
||
| Tenofovir disoproxil fumarate Entecavir 736 | Green: Administer standard doses | Administer standard doses | No significant change |
1 mg once daily | No significant change |
||
| Tenofovir disoproxil fumarate RAL 735 | Green: Administer standard doses | Administer standard doses | Cmax decrease 23%, AUC decrease 10%, Cmin decrease 13% |
400 mg BID | Cmax increase 64%, AUC increase 49% |
||
| Tenofovir disoproxil fumarate 3TC 734 | Green: Administer standard doses | Administer standard doses | No significant change |
150 mg BID | Cmax decrease 24% |
||
| Tenofovir disoproxil fumarate ETR 733 | Green: Administer standard doses | Administer standard doses | Cmax increase 15%, AUC increase 15%, Cmin increase 19% |
200 mg BID | Cmax decrease 19%, AUC decrease 19%, Cmin decrease 18% |
||
| Tenofovir disoproxil fumarate SOF 732 | Green: Administer standard doses | Administer standard doses | Cmax increase 25% |
400 mg x 1 | Cmax decrease 19% |
||
| Tenofovir disoproxil fumarate G/P 731 | Green: Administer standard doses | Administer standard doses | (when given with EFV / FTC) |
Not studied (may increase TDF levels) |
Not studied |
||
| Tenofovir disoproxil fumarate RPV 730 | Green: Administer standard doses | Administer standard doses | Potentially increased risk of TDF adverse effects |
Cmax increase 19%, AUC increase 23%, Cmin increase 24% |
150 mg once daily | No significant change |
Use recommended dose of rilpivirine 25 mg |
| Tenofovir alafenamide SOF/VEL 715 | Green: Administer standard doses | Administer standard doses | Cmax decreased 20%, AUC decreased 13% |
400 / 100mg once daily | Sofosbuvir: Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite: Cmax increased 29%, AUC increased 48%, Cmin increased 58%; velpatasvir: Cmax increased 30%, AUC increased 50%, Cmin increased 60% |
||
| Tenofovir alafenamide SOF/VEL/VOX 714 | Green: Administer standard doses | Administer standard doses | Cmax decreased 21%; AUC decreased 7% |
400 / 100 / 100mg + 100mg voxilaprevir once daily | Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3% |
||
| Tenofovir alafenamide SOF/VEL/VOX 713 | Green: Administer standard doses | Administer standard doses | Cmax increased 28%, AUC increased 57% |
400 / 100 / 100 + 100 once daily | Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3% |
||
| Tenofovir alafenamide EFV 712 | Green: Administer standard doses | Administer standard doses | Cmin decreased 22%, AUC decreased 14% |
600 mg once daily | Not studied |
||
| Tenofovir alafenamide LDV/SOF 711 | Green: Administer standard doses | Administer standard doses | Cmax decreased 10%; AUC decreased 14% |
90 / 400 mg once daily | Not reported |
||
| Tenofovir alafenamide EE/NGM 710 | Green: Administer standard doses | Administer standard doses | Not studied |
NGM 0.180 / 0.215 / 0.250mg once daily with EE 0.025mg once daily | Norgestromin: Cmax increased 17%, AUC increased 12%, Cmin increased 16%; norgestrel: Cmax increased 10%, AUC increased 9%, Cmin increased 11%; EE: Cmax increased 22%, AUC increased 11%, Cmin increased 2% |
||
| Tenofovir alafenamide Midazolam 709 | Green: Administer standard doses | Administer standard doses | Not studied |
2.5mg once daily (PO); 1mg once daily (IV) | midazolam (2.5mg PO): Cmax increased 2%, AUC increased 12%; midazolam (1mg IV): Cmax decreased 1%, AUC increased 8% |
||
| Tenofovir alafenamide LDV/SOF 708 | Green: Administer standard doses | Administer standard doses | Cmax increased 3 - 17%, AUC increased 27-32% |
90 / 400 mg once daily | Ledipasvir: Cmax increased 1%, AUC increased 2%, Cmin increased 2%; sofosbuvir: Cmax decreased 4%, AUC increased 5%; sofosbuvir metabolite: Cmax 8%, AUC increased 8%, Cmin increased 10% |
||
| Tenofovir alafenamide DRV/c 707 | Green: Administer standard doses | Administer standard doses | Cmax decreased 7%, AUC decreased 2% |
800 / 150 mg once daily | Cmax increased 2%, AUC decreased 1%, Cmin decreased 3% |
||
| Tenofovir alafenamide DTG 706 | Green: Administer standard doses | Administer standard doses | Cmax increased 24%, AUC increased 19% |
50 mg once daily | Cmax increased 15%, AUC increased 2%, Cmin increased 5% |
